本帖最后由 老马 于 2012-1-13 21:20 编辑
7 Y9 v, e& ^1 Q J% s: t; |8 X, X" ]* F' O
爱必妥和阿瓦斯丁的比较
" M5 s, [7 \" @. H! T6 Z5 X& I
. u4 |/ H% }7 phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/, n7 n3 W [' J$ L* Y: M6 ^$ c
3 r3 Y8 J4 K x9 F6 Q
6 t0 u* I8 Y D7 f, E: X9 Mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. |+ t( Z7 ~3 r: y==================================================
# t0 [" a: T0 `9 B7 `8 FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: @: h. V) E# C8 s( _8 APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# n8 g0 s; ?: b9 Q \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' p6 h/ P8 F8 c" A; D
|